Ovarian Cancer - Articles and news items

Lynparza Phase III data demonstrates progression-free survival in ovarian cancer

Industry news / 17 March 2017 / Niamh Marriott, Junior Editor

AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95% CI 0.22 to 0.41; P<0.0001; […]

Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer…

Aprea announces efficacy and safety data for APR-246 in ovarian cancer

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting…

NICE says ‘yes’ to two ovarian cancer drugs, rejects three

Industry news / 27 April 2016 / Victoria White, Digital Content Producer

The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment…

TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study

Industry news / 22 April 2016 / Victoria White, Digital Content Producer

TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer…

ImmunoGen and Merck collaborate for ovarian cancer trial

Industry news / 5 February 2016 / Victoria White

The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer…

FDA grants Fast Track Designation to TapImmune’s TPIV 200

Industry news / 3 February 2016 / Victoria White

The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer…

FDA finally speeds up approval for ovarian cancer drugs

Blog / 19 January 2016 / Snehal Chougule, Allied Market Research

Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration…

Trial to investigate avelumab and entinostat in ovarian cancer

Industry news / 4 January 2016 / Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells…

Merck KGaA and Pfizer advance avelumab clinical development programme

Industry news / 22 December 2015 /

Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer…

EMA grants Orphan Drug Designation for Debio 1143

Industry news / 8 December 2015 / Victoria White

Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer…

Aprea announces preliminary study data for APR-246 in ovarian cancer

Industry news / 26 October 2015 / Victoria White

APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...